{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:52:25Z","timestamp":1792479145262,"version":"4.5.0"},"reference-count":73,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) have reshaped the treatment landscape of urothelial carcinoma (UC) by enabling selective delivery of highly potent cytotoxic agents to tumor cells. Enfortumab vedotin, sacituzumab govitecan, and HER2-directed ADCs have demonstrated meaningful clinical activity across metastatic and earlier disease settings, with enfortumab vedotin plus pembrolizumab now established as a first-line standard of care. Despite these advances, therapeutic responses remain heterogeneous, and resistance frequently limits durability. This review summarizes current knowledge on predictors of response and mechanisms of resistance to ADCs in UC, highlighting the roles of target antigen expression and heterogeneity, genomic alterations, payload sensitivity, drug efflux transporters, and tumor microenvironmental factors. We discuss emerging biomarkers beyond antigen abundance, patterns of cross-resistance and treatment sequencing, and evolving strategies to overcome resistance, including next-generation ADC design and rational combination therapies. Advancing biomarker-driven patient selection and addressing mechanisms of resistance will be critical to maximizing the durability and clinical impact of ADCs in urothelial carcinoma.<\/jats:p>","DOI":"10.3390\/curroncol33020103","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:35:37Z","timestamp":1770287737000},"page":"103","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma"],"prefix":"10.3390","volume":"33","author":[{"given":"Jing","family":"Huang","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ademola","family":"Ojo","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-0267","authenticated-orcid":false,"given":"Bobby","family":"Liaw","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.path.2021.05.005","article-title":"Molecular Pathology of Urothelial Carcinoma","volume":"14","author":"Netto","year":"2021","journal-title":"Surg. Pathol. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cll.2023.08.010","article-title":"Molecular Pathology of Urothelial Carcinoma","volume":"44","author":"Netto","year":"2024","journal-title":"Clin. Lab. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kwon, W.-A., Seo, H.K., Song, G., Lee, M.-K., and Park, W.S. (2025). Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010086"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e471924","DOI":"10.1200\/EDBK-25-471924","article-title":"Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma","volume":"45","author":"Zarrabi","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ajur.2016.09.005","article-title":"Understanding the Biology of Urothelial Cancer Metastasis","volume":"3","author":"Kobayashi","year":"2016","journal-title":"Asian J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody Drug Conjugate: The \u201cBiological Missile\u201d for Targeted Cancer Therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., Padala, S.A., and Barsouk, A. (2020). Epidemiology of Bladder Cancer. Med. Sci., 8.","DOI":"10.3390\/medsci8010015"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.3346\/jkms.2024.39.e320","article-title":"FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development","volume":"39","author":"Kwon","year":"2024","journal-title":"J. Korean Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","article-title":"Tumor Initiation and Early Tumorigenesis: Molecular Mechanisms and Interventional Targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and Clinical Significance of Histological Variants of Bladder Cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sabit, H., Arneth, B., Abdel-Ghany, S., Madyan, E.F., Ghaleb, A.H., Selvaraj, P., Shin, D.M., Bommireddy, R., and Elhashash, A. (2024). Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression. Cells, 13.","DOI":"10.3390\/cells13191666"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.yao.2023.01.010","article-title":"The Future of Antibody\u2013Drug Conjugates in Urothelial Cancer","volume":"3","author":"Goodson","year":"2023","journal-title":"Adv. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): Current and Future Biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"122910","DOI":"10.1016\/j.lfs.2024.122910","article-title":"Nectin-4-Directed Antibody-Drug Conjugates (ADCs): Spotlight on Preclinical and Clinical Evidence","volume":"352","author":"Khosravanian","year":"2024","journal-title":"Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhang, F., and Li, S. (2025). Antibody-Drug Conjugates as Game Changers in Bladder Cancer: Current Progress and Future Directions. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1591191"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.urolonc.2023.06.006","article-title":"Antibody-Drug Conjugates for Urothelial Carcinoma","volume":"41","author":"Thomas","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11795549241290787","DOI":"10.1177\/11795549241290787","article-title":"The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer","volume":"18","author":"Vlachou","year":"2024","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_19","first-page":"1132","article-title":"Advances in Antibody-Drug Conjugates for Urothelial Carcinoma Treatment","volume":"22","author":"Wei","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kwon, W.-A., Lee, S.-Y., Jeong, T.Y., Kim, H.H., and Lee, M.-K. (2024). Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development. Cancers, 16.","DOI":"10.3390\/cancers16132420"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing after Platinum-Based Chemotherapy and Checkpoint Inhibitors: Updated Safety and Efficacy Outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2022.40.16_suppl.4519","article-title":"A Phase II Study of RC48-ADC in HER2-Negative Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2021.39.6_suppl.394","article-title":"EV-201 Cohort 2: Enfortumab Vedotin in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1\/PD-L1 Inhibitors","volume":"39","author":"Balar","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab Alone or Combined with Chemotherapy versus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-Label, Phase 3 Trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-Controlled Phase 3 Trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab Govitecan in Advanced Urothelial Carcinoma: TROPiCS-04, a Phase III Randomized Trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_29","first-page":"47","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2024.42.4_suppl.625","article-title":"Phase Ib Trial of Erdafitinib (E) Combined with Enfortumab Vedotin (EV) Following Platinum and PD-1\/L1 Inhibitors for Metastatic Urothelial Carcinoma (mUC) with FGFR2\/3 Genetic Alterations (GAs)","volume":"42","author":"Jain","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1200\/JCO.2023.41.16_suppl.4596","article-title":"A First-in-Human Trial of Intravesical Enfortumab Vedotin (EV), an Antibody-Drug Conjugate (ADC), in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC): Interim Results of a Phase 1 Study (EV-104)","volume":"41","author":"Kamat","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","unstructured":"Vulsteke, C. (2025, January 02). ESMO 2025: Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (Pembro) in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible: The Phase 3 KEYNOTE-905 Study. Available online: https:\/\/www.urotoday.com\/conference-highlights\/esmo-2025\/esmo-2025-bladder-cancer\/164060-esmo-2025-perioperative-enfortumab-vedotin-ev-plus-pembrolizumab-pembro-in-participants-with-muscle-invasive-bladder-cancer-mibc-who-are-cisplatin-ineligible-the-phase-3-keynote-905-study.html."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1200\/JCO.2024.42.16_suppl.4586","article-title":"Updated Interim Analysis of a Phase I\/Ib Study of Enfortumab Vedotin plus Cabozantinib in Patients with Metastatic Urothelial Carcinoma","volume":"42","author":"Brown","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Maiorano, B.A., Catalano, M., Maiello, E., and Roviello, G. (2023). Enfortumab Vedotin in Metastatic Urothelial Carcinoma: The Solution EVentually?. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1254906"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S1487","DOI":"10.1016\/j.annonc.2025.08.3688","article-title":"ESMO 2025: EV-103 Cohort K: Efficacy and Safety of Enfortumab Vedotin with or without Pembrolizumab in Cisplatin-Ineligible Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer with a Median Follow-up of ~3.5 Years","volume":"36","author":"Friedlander","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-023-01475-9","article-title":"Novel ADCs and Combination Therapy in Urothelial Carcinoma: Latest Updates from the 2023 ASCO-GU Cancers Symposium","volume":"16","author":"Yu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"Tran","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S1137","DOI":"10.1016\/j.annonc.2024.08.2051","article-title":"1966MO EV-302: Exploratory Analysis of Nectin-4 Expression and Response to 1L Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (La\/mUC)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.2025.43.5_suppl.664","article-title":"EV-302: Updated Analysis from the Phase 3 Global Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV + P) vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (La\/mUC)","volume":"43","author":"Powles","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1002307","DOI":"10.37349\/etat.2025.1002307","article-title":"Strategies to Overcome Resistance to Enfortumab Vedotin and Pembrolizumab for Patients with Urothelial Carcinoma: Harnessing Present Knowledge for Future Advances","volume":"6","author":"Jang","year":"2025","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Jindal, T., Jiang, C.Y., Alhalabi, O., Nguyen, C.B., Oh, E., Tsung, I., Bakaloudi, D.R., Talukder, R., Davidsohn, M., and Freeman, D. (2025). Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur. Urol., in press.","DOI":"10.1016\/j.eururo.2025.09.003"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"116152","DOI":"10.1016\/j.biopha.2024.116152","article-title":"Emerging Strategy for the Treatment of Urothelial Carcinoma: Advances in Antibody-Drug Conjugates Combination Therapy","volume":"171","author":"You","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2023.41.16_suppl.4572","article-title":"Biomarkers of Response to Sacituzumab Govitecan (SG) and Efficacy after Treatment with Enfortumab Vedotin (EV) in Advanced Urothelial Carcinoma (aUC): Analysis of the UNITE Study","volume":"41","author":"Jindal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S1149","DOI":"10.1016\/j.annonc.2024.08.2073","article-title":"1988P Enfortumab Vedotin (EV) + Pembrolizumab (P) Outcomes Outside Clinical Trials and Biomarkers of Benefit in Patients (Pts) with Advanced Urothelial Carcinoma: Analysis of the UNITE Study","volume":"35","author":"Jindal","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1200\/JCO.2023.41.16_suppl.4573","article-title":"Independent Biomarkers Predictive of Outcomes with Enfortumab Vedotin (EV) in Patients (Pts) with Advanced Urothelial Carcinoma (aUC): Analysis of the UNITE Study","volume":"41","author":"Jindal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105305","DOI":"10.1016\/j.esmoop.2025.105305","article-title":"Real-World Clinical Outcomes of Sacituzumab Govitecan after Prior Exposure to Enfortumab Vedotin in Patients with Metastatic Urothelial Carcinoma","volume":"10","author":"Sternschuss","year":"2025","journal-title":"ESMO Open"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., and Lecesne, A. (2023). Mechanisms of Resistance to Antibody-Drug Conjugates. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119674"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2024.42.4_suppl.690","article-title":"Mechanisms and Strategies to Overcome Resistance to Enfortumab Vedotin in Bladder Cancer","volume":"42","author":"Chang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-22-0013","article-title":"Overcoming Resistance to Anti\u2013Nectin-4 Antibody-Drug Conjugate","volume":"21","author":"Crompot","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/iju5.12696","article-title":"Increased Expression of ATP-Binding Cassette Transporters in Enfortumab Vedotin-Resistant Urothelial Cancer","volume":"7","author":"Kotono","year":"2024","journal-title":"IJU Case Rep."},{"key":"ref_53","unstructured":"(2025, January 02). ASCO 2025: EV-103 Cohort H: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer\u20143-Year Efficacy Results. Available online: https:\/\/www.urotoday.com\/conference-highlights\/asco-2025\/asco-2025-bladder-cancer\/161036-asco-2025-ev-103-cohort-h-neoadjuvant-treatment-with-enfortumab-vedotin-monotherapy-in-cisplatin-ineligible-patients-with-muscle-invasive-bladder-cancer-3-year-efficacy-results.html."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","article-title":"Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models","volume":"19","author":"Kulukian","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_55","first-page":"728","article-title":"AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody\u2013Drug Conjugate Production","volume":"34","author":"Fujii","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next Generation of Antibody\u2013Drug Conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Majumder, A. (2023). HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer. Cells, 12.","DOI":"10.3390\/cells12212517"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO-25-00109","article-title":"Efficacy and Safety of BL-B01D1 in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial","volume":"43","author":"Bian","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"215969","DOI":"10.1016\/j.canlet.2022.215969","article-title":"Drug Conjugate-Based Anticancer Therapy\u2014Current Status and Perspectives","volume":"552","author":"Yang","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","article-title":"BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors","volume":"21","author":"Rigby","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"CT084","DOI":"10.1158\/1538-7445.AM2024-CT084","article-title":"Abstract CT084: A Phase 1 Study of LY4101174 (ETx-22), an Antibody-Drug Conjugate Targeting Nectin-4, in Patients with Advanced or Metastatic Urothelial Cancer and Other Solid Tumors (Trial in Progress)","volume":"84","author":"Rosenberg","year":"2024","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2025.43.5_suppl.807","article-title":"Phase I Dose-Escalation Study of the next-Generation Nectin-4 Targeting Antibody\u2013Drug Conjugate CRB-701 (SYS6002) in US and UK Patients with Urothelial Cancer and Other Solid Tumors","volume":"43","author":"Perez","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1200\/JCO.2024.42.16_suppl.3013","article-title":"9MW2821, a Nectin-4 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumor: Results from a Phase 1\/2a Study","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1200\/JCO.2025.43.5_suppl.796","article-title":"Efficacy and Safety of Sacituzumab Tirumotecan Monotherapy in Patients with Advanced Urothelial Carcinoma Who Progressed on or after Prior Anti-Cancer Therapies: Report from the Phase 1\/2 MK-2870-001 Study","volume":"43","author":"Ye","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"TPS3153","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3153","article-title":"TROPION-PanTumor03: Phase 2, Multicenter Study of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients (Pts) with Advanced\/Metastatic Solid Tumors","volume":"41","author":"Janjigian","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S1590","DOI":"10.1016\/j.annonc.2025.08.3686","article-title":"3072MO Datopotamab Deruxtecan (Dato-DXd) + Rilvegostomig (Rilve) in Patients (Pts) with Locally Advanced or Metastatic Urothelial Cancer (a\/mUC): Results from the Phase II TROPION-PanTumor03 Study","volume":"36","author":"Rha","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1200\/JCO.2025.43.16_suppl.3024","article-title":"BAT8008, a TROP-2 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumor: Results from a Phase 1 Study","volume":"43","author":"Zhao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1535-7163.MCT-24-0588","article-title":"OBI-992, a Novel TROP2-Targeted Antibody\u2013Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models","volume":"24","author":"Li","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1158\/1538-7445.AM2024-7179","article-title":"Abstract 7179: OBI-992, a Novel TROP2 Targeting Antibody Drug Conjugate Demonstrates Superior in Vivo PK\/PD Properties and a Favorable Safety Profile","volume":"84","author":"Shia","year":"2024","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1158\/1078-0432.CCR-22-3627","article-title":"Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma","volume":"30","author":"Petrylak","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"TPS3157","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3157","article-title":"IDeate-PanTumor02: A Phase 1b\/2 Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Patients (Pts) with Recurrent or Metastatic Solid Tumors","volume":"43","author":"Kogawa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"114096","DOI":"10.1016\/j.ejca.2024.114096","article-title":"A Single-Arm, Multicenter, Phase 2 Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate (MRG002) in HER2-Positive Unresectable Locally Advanced or Metastatic Urothelial Carcinoma","volume":"205","author":"Qu","year":"2024","journal-title":"Eur. J. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/103\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:14:39Z","timestamp":1770290079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020103"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020103","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}